Welcome to SAMHSA's Publications site. In the future, you may be asked to respond to a CAPTCHA to access the site for added security.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
This comprehensive kit provides substance use disorder treatment professionals with a year-long intensive outpatient treatment model. Professionals can use this model when treating clients who are dependent on stimulant drugs, such as methamphetamine and cocaine. Access family education sessions and handouts.
This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.
This manual guides physicians in the use of medications to help patients achieve abstinence from alcohol. It describes how the medications work, whom they benefit, and side effects for three FDA-approved medications: acamprosate, disulfiram, and naltrexone.
Millions of Americans have a substance use disorder. Find a treatment facility near you.
Free and confidential support for people in distress, 24/7.
Find treatment facilities confidentially and anonymously, 24/7.
Treatment referral and information, 24/7.